Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pico-Tesla To File De Novo 510(k) In 2011 To Treat Parkinson's With Magnets

This article was originally published in The Gray Sheet

Executive Summary

Pico-Tesla Magnetic Therapies plans to submit a de novo 510(k) application in early 2011 to treat Parkinson's disease symptoms with a low-level electromagnetic field, according to the company

You may also be interested in...



Pico-Tesla plans atrial fibrillation trial

Pico-Tesla will begin a U.S. clinical trial of its Resonator electromagnetic field generator to treat paroxysmal atrial fibrillation in the fourth quarter, according to the company. Clinical trials are already ongoing for use of the device to create low-level electromagnetic fields (EMF) to treat Parkinson's disease and type-2 diabetes. In May, a dog study at the University of Oklahoma's Heart Rhythm Institute suggested EMF fields from the device can terminate and prevent atrial fibrillation. The so-called Magneceutical therapy system comprises two large magnetic coils; patients sit between the coils for treatment (1"The Gray Sheet" Nov. 9, 2009)

Pico-Tesla plans atrial fibrillation trial

Pico-Tesla will begin a U.S. clinical trial of its Resonator electromagnetic field generator to treat paroxysmal atrial fibrillation in the fourth quarter, according to the company. Clinical trials are already ongoing for use of the device to create low-level electromagnetic fields (EMF) to treat Parkinson's disease and type-2 diabetes. In May, a dog study at the University of Oklahoma's Heart Rhythm Institute suggested EMF fields from the device can terminate and prevent atrial fibrillation. The so-called Magneceutical therapy system comprises two large magnetic coils; patients sit between the coils for treatment (1"The Gray Sheet" Nov. 9, 2009)

Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar

FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis

Related Content

Topics

UsernamePublicRestriction

Register

MT028150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel